# Combined Anabolic Therapy

> **NCT06558188** · PHASE4 · RECRUITING · sponsor: **Massachusetts General Hospital** · enrollment: 50 (estimated)

## Conditions studied

- Osteoporosis, Postmenopausal
- Osteoporosis

## Interventions

- **DRUG:** Romosozumab
- **DRUG:** Teriparatide

## Key facts

- **NCT ID:** NCT06558188
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-03
- **Primary completion:** 2027-12-30
- **Final completion:** 2028-04-01
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-04-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06558188

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06558188, "Combined Anabolic Therapy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06558188. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*